HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Animal testing

This article was originally published in The Rose Sheet

Executive Summary

Corrositex synthetic skin test accepted as an in vitro replacement to traditional animal tests for dermal corrosivity by the Environmental Protection Agency, Occupational Safety & Health Administration and Consumer Product Safety Commission, the National Institute's of Health's National Toxicology Program announces. The approval will be formally announced in upcoming Federal Register notices. InVitro International's Corrositex is an alternative to an existing in vivo method that involves testing several thousand laboratory rabbits each year. The Inter-Agency Coordinating Committee for the Validation of Alternative Methods unanimously recommended Corrositex in June 1999 (1"The Rose Sheet" June 28, 1999, p. 12). Corrositex is the second ICCVAM-recommended test to receive governmental approval; murine LLNA was accepted in January (2"The Rose Sheet" Jan. 10, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel